Safe and effective gene transfer by adeno-associated virus of neonatal thymus-derived mesenchymal stromal cells

2011 ◽  
Vol 43 (2) ◽  
pp. 108-114 ◽  
Author(s):  
W.I. Lee ◽  
M. Khim ◽  
I.R. Im ◽  
O. Shin ◽  
J.W. Park ◽  
...  
2007 ◽  
Vol 9 (1) ◽  
pp. 22-32 ◽  
Author(s):  
Keefe Chng ◽  
Stephen R. Larsen ◽  
Shangzhen Zhou ◽  
J. Fraser Wright ◽  
Rosetta Martiniello-Wilks ◽  
...  

2019 ◽  
Vol 8 (9) ◽  
pp. 1326
Author(s):  
Stephanie Morscheid ◽  
Jagadeesh Kumar Venkatesan ◽  
Ana Rey-Rico ◽  
Gertrud Schmitt ◽  
Magali Cucchiarini

The application of chondrogenic gene sequences to human bone marrow-derived mesenchymal stromal cells (hMSCs) is an attractive strategy to activate the reparative activities of these cells as a means to enhance the processes of cartilage repair using indirect cell transplantation procedures that may improve the repopulation of cartilage lesions. In the present study, we examined the feasibility of co-delivering the highly competent transforming growth factor beta (TGF-β) with the insulin-like growth factor I (IGF-I) in hMSCs via recombinant adeno-associated virus (rAAV) vector-mediated gene transfer prior to implantation in a human model of osteochondral defect (OCD) ex vivo that provides a microenvironment similar to that of focal cartilage lesions. The successful co-overexpression of rAAV TGF-β/IGF-I in implanted hMSCs promoted the durable remodeling of tissue injury in human OCDs over a prolonged period of time (21 days) relative to individual gene transfer and the control (reporter lacZ gene) treatment, with enhanced levels of cell proliferation and matrix deposition (proteoglycans, type-II collagen) both in the lesions and at a distance, while hypertrophic, osteogenic, and catabolic processes could be advantageously delayed. These findings demonstrate the value of indirect, progenitor cell-based combined rAAV gene therapy to treat human focal cartilage defects in a natural environment as a basis for future clinical applications.


PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0237479
Author(s):  
Manuel Weißenberger ◽  
Manuela H. Weißenberger ◽  
Mike Wagenbrenner ◽  
Tizian Heinz ◽  
Jenny Reboredo ◽  
...  

2008 ◽  
Vol 40 (2) ◽  
pp. 278
Author(s):  
Irina Nifontova ◽  
Daria Svinareva ◽  
Natalia Sats ◽  
Vadim Surin ◽  
Nina Drize

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1136
Author(s):  
Robin Nilson ◽  
Olivia Lübbers ◽  
Linus Weiß ◽  
Karmveer Singh ◽  
Karin Scharffetter-Kochanek ◽  
...  

Human multipotent mesenchymal stromal cells (hMSCs) are currently developed as cell therapeutics for different applications, including regenerative medicine, immune modulation, and cancer treatment. The biological properties of hMSCs can be further modulated by genetic engineering. Viral vectors based on human adenovirus type 5 (HAdV-5) belong to the most frequently used vector types for genetic modification of human cells in vitro and in vivo. However, due to a lack of the primary attachment receptor coxsackievirus and adenovirus receptor (CAR) in hMSCs, HAdV-5 vectors are currently not suitable for transduction of this cell type without capsid modification. Here we present several transduction enhancers that strongly enhance HAdV-5-mediated gene transfer into both bone marrow- and adipose tissue-derived hMSCs. Polybrene, poly-l-lysine, human lactoferrin, human blood coagulation factor X, spermine, and spermidine enabled high eGFP expression levels in hMSCs. Importantly, hMSCs treated with enhancers were not affected in their migration behavior, which is a key requisite for many therapeutic applications. Exemplary, strongly increased expression of tumor necrosis factor (TNF)-stimulated gene 6 (TSG-6) (a secreted model therapeutic protein) was achieved by enhancer-facilitated HAdV-5 transduction. Thus, enhancer-mediated HAdV-5 vector transduction is a valuable method for the engineering of hMSCs, which can be further exploited for the development of innovative hMSC therapeutics.


2019 ◽  
Vol 166 (4) ◽  
pp. 527-534
Author(s):  
E. S. Zubkova ◽  
I. B. Beloglazova ◽  
E. G. Evtushenko ◽  
A. T. Kopylov ◽  
E. K. Shevchenko ◽  
...  

2016 ◽  
Vol 24 (7) ◽  
pp. 1227-1236 ◽  
Author(s):  
Nathan Paul Sweeney ◽  
Cathy Regan ◽  
Jiahui Liu ◽  
Antonio Galleu ◽  
Francesco Dazzi ◽  
...  

Cytotherapy ◽  
2012 ◽  
Vol 14 (5) ◽  
pp. 529-539 ◽  
Author(s):  
Cheng Jun ◽  
Zhang Zhihui ◽  
Wei Lu ◽  
Nong Yaoming ◽  
Wen Lei ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 409-409
Author(s):  
Masami Watanabe ◽  
Atsushi Nagai ◽  
Norihiro Kusumi ◽  
Yasutomo Nasu ◽  
Hiromi Kumon ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 267-267
Author(s):  
Ichiro Yoshimura ◽  
Yasunori Mizuguchi ◽  
Akira Miyajima ◽  
Tomohiko Asano ◽  
Hiroaki Mizukami ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document